As of 2025-12-16, the Fair Value of Supernus Pharmaceuticals Inc (SUPN) is -8.33 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 47.28 USD, the upside of Supernus Pharmaceuticals Inc is -117.63%.
With the market price of 47.28 USD and our fair value calculation, Supernus Pharmaceuticals Inc (SUPN) is not a good investment. Investing in SUPN stocks now will result in a potential loss of 117.63%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | 127.00 | 53.40 | 60.70 | 1.32 | 73.86 | 63.26 |
| YoY growth | 12.29% | -57.95% | 13.67% | -97.83% | 5,512.84% | 1,076.60% |
| Market Cap (mil) | 2,711.04 |
| P/E | |
| Forward P/E | 34.15x |
| EPS | -0.33 |
| Avg earnings growth rate | 1,076.60% |
| TTM earnings | -19.12 |